By Bahar YukselThe role of hormonal treatment after endometriosis surgery
By Bahar Yuksel
Postoperative hormonal suppression after endometriosis surgery still does not have a uniform approach. The meta-analysis study conducted by Zakhari et al. aimed to find a significant answer regarding this burden. They analyzed the database systems including MEDLINE, Embase, Cochrane CENTRAL,…
Key Points Lay Summary
By Irem OnurA hope for postoperative symptomatic endometriosis therapy
By Irem Onur
A new chapter in the treatment of symptomatic endometriosis patients may begin since new medical approaches including oral GnRH antagonists, selective progesterone receptor modulators, aromatase inhibitors, and peritoneal immune response modulators are being actively evaluated. To date, there was only…
Key Points Lay Summary
By Dr. Youngran ParktRNA-derived fragments in ovarian endometriosis?
By Dr. Youngran Park
Endometriosis is an estrogen-dependent mysterious disorder characterized by the presence of endometrium outside the normal location of the uterus cavity. This disease affects approximately 10% of reproductive-aged women and becomes a major reason for infertility in reproductive-aged women and dysmenorrhea…
Key Points Lay Summary
By Selma OransayA new trial to reduce the failure of IVF/ICS protocols in severe endometriosis
By Selma Oransay
Kong et al., from the first affiliated hospital of Zhengzhou University, China, recently published this single-blinded, a multicentered and randomized controlled study in the Journal of Reproductive Health, with the aim to find a safer and more effective ovulation induction regimen for patients with…
Key Points Lay Summary
By Hale Goksever CelikEndometriosis and female pelvic pain in all aspects
By Hale Goksever Celik
Endometriosis is defined as the localization of endometrial glandular and stromal tissue outside the uterine cavity. The prevalence of the disease ranges between 6-10% in reproductive-aged women. However, endometriosis is more frequently encountered in women with chronic pelvic pain and…
Key Points Lay Summary
By Özge ÖzkayaThe use of Elagolix in Women with Liver and Kidney Impairments
By Özge Özkaya
Elagolix may be used in women with moderate liver impairment, when necessary, for up to six months at a dose of 150 mg a day, according to a study published in the scientific journal Clinical Pharmacology in Drug Development. The…
Key Points Lay Summary
Best endometriosis articles of the past year.
By Selma Oransay
Dr.Stowall, from the Department of Obstetrics and Gynecology of Methodist Hospital, Dallas, Texas, USA penned this letter and recently published it in the Journal of Obstetrics and Gynecology to show his remarks of importance on four best publications of the…
Key Points Lay Summary
FDA Approves Endometriosis Pain Treatment
By Özge Özkaya
The U.S. Food and Drug Administration (FDA) approved a new medication for the treatment of moderate to severe pain associated with endometriosis, making it the first treatment to be approved in 10 years. The decision was announced in the Journal…
Key Points Lay Summary
By Murat OsmanEmerging medical treatments for endometriosis
By Murat Osman
Endometriosis is a disease whereby uterine tissue grows outside the walls of the uterus to the surfaces of other tissues in the body. It is a chronic disease and relies upon estrogen to grow and survive. Current medical therapies take…
Key Points Lay Summary
Could Endometriosis Be Caused by Bacteria?
By Özge Özkaya
A new concept called the bacterial contamination hypothesis in endometriosis has been proposed for the first time by researchers in Japan. This means that new potential therapies approaches could exist for this condition in addition to the conventional estrogen-suppressing therapies.…
Key Points Lay Summary
Treatment of Endometriosis in Adolescents
By Özge Özkaya
Most women with endometriosis who have been treated with Lupron plus add back as adolescents felt the treatment was effective in reducing the pain caused by the condition, according to a study published in the Journal of Pediatric & Adolescent…
Key Points Lay Summary
Investigational Medical Therapies for Endometriosis: Current Data and Future Trends.
By Dr. Youngran Park
The medical treatment of endometriosis has traditionally relied on hormonal therapies. Because these hormonal therapies preclude fertility or may have unwanted side effects, there is a great need for novel hormonal and non-hormonal medical options. Therefore, this review focuses on…
Key Points Lay Summary
By Kasthuri NairEFA Medical Conference 2017: "Hormone and Cytokine Sensitivity in Endometriosis" Presentation by Dr. Robert Taylor
By Kasthuri Nair
The first presenter of the “Estrogen from Inflammation to Cancer: A Distant Link?” section of EFA 2017 Medical Conference was Dr. Robert Taylor from Wake Forest University Health Sciences. Dr. Taylor’s presentation was titled “Hormone and Cytokine Sensitivity in Endometriosis.”…
Key Points Lay Summary
By Yu YuThe dose of the GnRHa after laparoscopic surgery
By Yu Yu
Laparoscopic surgery is considered a routine way to diagnose and remove endometriosis. The primary concern with laparoscopic surgery is the recurrence of endometriosis because of incomplete lesion excision. Hence, the challenge is to decrease endometriosis recurrence rate. Gonadotrophin-releasing hormone agonist…
Key Points Lay Summary
By Asli Bahadirli TalbottInhibition of key neurotransmitter could reduce endometriosis-related pain
By Asli Bahadirli Talbott
This study published in the scientific journalMolecular MedicineReports[link] by Lian et al. from Shanghai, China, aims to explore the relationship between transient receptor potential vanilloid type 1 (TRPV1) and endometriosis-associated pain. Pain is the most common symptom for women with…
Key Points Lay Summary
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
By Yu Yu
Taylor et al. presented an exciting recent study in The New England Journal of Medicine. This article reported the results from a multicentre, double-blind, randomized, placebo-controlled phase 3 trials of elagolix for the treatment of endometriosis-associated pain. As women with…
Key Points Lay Summary
Elagolix (ABT-620) for endometriosis pain?
By Yu Yu
Elagolix is an orally active gonadotropin-releasing hormone antagonist that has just recently completed Phase 3 clinical trial for endometriosis-associated pain (NCT01931670). The review article by Alessandro et al in Archives of Gynecology and Obstetrics summarized the current research findings on…
Key Points Lay Summary